Use of alternative receptors different than alpha-dystroglycan by selected isolates of lymphocytic choriomeningitis virus.
Long-term infections with viruses permit the generation of variants that evolve specific growth advantages in certain tissues and may show altered disease potentials. The selection of such variants is influenced by the host tissue and often involves virus-receptor interactions. Here we report studies of receptor usage by several lymphocytic choriomeningitis virus (LCMV) isolates that expressed different disease patterns. Consistent with our previous studies, we found that, with one exception, multiple LCMV variants that cause suppression of immune responses bound with high affinity to their cellular receptor alpha-dystroglycan (alpha-DG) and were dependent on alpha-DG for entry and infection. The exception also bound strongly to alpha-DG but was not dependent on alpha-DG for entry and infection. In contrast, those variants of LCMV that do not suppress the immune response either displayed low or no binding affinity for alpha-DG and used alternative receptors in addition to or instead of alpha-DG for entry and infection. For all alpha-DG binding variants, alpha-DG represents the preferred receptor in DG-expressing cells, as soluble alpha-DG blocked their infection of DG-deficient cells, indicating that binding of alpha-DG to the viral glycoprotein (GP) at the virion surface interferes with the GP's interaction with the alternative receptor. Biochemical characterization of the alternative receptor(s) for LCMV indicated that they are either protein(s) or protein-bound entities.
Kunz
Stefan
S
Division of Virology, Department of Neuropharmacology, The Scripps Research Institute, La Jolla, CA 92037, USA. stefanku@scripps.edu
Sevilla
Noemí
N
Rojek
Jillian M
JM
Oldstone
Michael B A
MB
D000818:Animals; D002478:Cells, Cultured; D003598:Cytoskeletal Proteins / Q000172:deficiency / Q000235:genetics / Q000502:physiology*; D049030:Dystroglycans; D006023:Glycoproteins / Q000378:metabolism; D066298:In Vitro Techniques; D008217:Lymphocytic choriomeningitis virus / Q000302:isolation & purification / Q000472:pathogenicity* / Q000502:physiology; D008562:Membrane Glycoproteins / Q000172:deficiency / Q000235:genetics / Q000502:physiology*; D051379:Mice; D018345:Mice, Knockout; D011485:Protein Binding; D011499:Protein Processing, Post-Translational; D011991:Receptors, Virus / Q000502:physiology*; D014764:Viral Proteins / Q000378:metabolism
D003598:Cytoskeletal Proteins; D006023:Glycoproteins; D008562:Membrane Glycoproteins; D011991:Receptors, Virus; D014764:Viral Proteins; D049030:Dystroglycans